

Jose Luis Jimenez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/568356/publications.pdf>

Version: 2024-02-01

69
papers

1,798
citations

218662

26
h-index

289230

40
g-index

74
all docs

74
docs citations

74
times ranked

2286
citing authors

#	ARTICLE	IF	CITATIONS
1	The Spanish HIV BioBank: a model of cooperative HIV research. <i>Retrovirology</i> , 2009, 6, 27.	2.0	142
2	Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). <i>Vaccine</i> , 2011, 29, 8309-8316.	3.8	70
3	Carbosilane Dendrimers to Transfect Human Astrocytes with Small Interfering RNA Targeting Human Immunodeficiency Virus. <i>BioDrugs</i> , 2010, 24, 331-343.	4.6	66
4	Highly Efficient Transfection of Rat Cortical Neurons Using Carbosilane Dendrimers Unveils a Neuroprotective Role for HIF-1 α in Early Chemical Hypoxia-Mediated Neurotoxicity. <i>Pharmaceutical Research</i> , 2009, 26, 1181-1191.	3.5	63
5	The HIV/AIDS Vaccine Candidate MVA-B Administered as a Single Immunogen in Humans Triggers Robust, Polyfunctional, and Selective Effector Memory T Cell Responses to HIV-1 Antigens. <i>Journal of Virology</i> , 2011, 85, 11468-11478.	3.4	63
6	Polyanionic carbosilane dendrimer-conjugated antiviral drugs as efficient microbicides: Recent trends and developments in HIV treatment/therapy. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 1481-1498.	3.3	60
7	Carbosilane dendrimers as gene delivery agents for the treatment of HIV infection. <i>Journal of Controlled Release</i> , 2014, 184, 51-57.	9.9	58
8	Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1833-1842.	3.0	56
9	Inhibition of Phosphodiesterase Type IV Suppresses Human Immunodeficiency Virus Type 1 Replication and Cytokine Production in Primary T Cells: Involvement of NF- κ B and NFAT. <i>Journal of Virology</i> , 1998, 72, 4712-4720.	3.4	56
10	Bryostatins activates HIV-1 latent expression in human astrocytes through a PKC and NF- κ B-dependent mechanism. <i>Scientific Reports</i> , 2015, 5, 12442.	3.3	53
11	Prevention vaginally of HIV-1 transmission in humanized BLT mice and mode of antiviral action of polyanionic carbosilane dendrimer G2-S16. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 1299-1308.	3.3	52
12	Synergistic activity profile of carbosilane dendrimer G2-STE16 in combination with other dendrimers and antiretrovirals as topical anti-HIV-1 microbicide. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, 609-618.	3.3	49
13	Gene Therapy in HIV-1 Infected Cells to Decrease Viral Impact by Using an Alternative Delivery Method. <i>ChemMedChem</i> , 2010, 5, 921-929.	3.2	48
14	A new tool for the paediatric HIV research: general data from the Cohort of the Spanish Paediatric HIV Network (CoRISpe). <i>BMC Infectious Diseases</i> , 2013, 13, 2.	2.9	46
15	Dendrimers as topical microbicides with activity against HIV. <i>New Journal of Chemistry</i> , 2012, 36, 299-309.	2.8	45
16	Synthesis, structure and molecular modelling of anionic carbosilane dendrimers. <i>Dalton Transactions</i> , 2012, 41, 12733.	3.3	45
17	Triple combination of carbosilane dendrimers, tenofovir and maraviroc as potential microbicide to prevent HIV-1 sexual transmission. <i>Nanomedicine</i> , 2015, 10, 899-914.	3.3	44
18	Mechanistic Studies of Viral Entry: An Overview of Dendrimer-Based Microbicides As Entry Inhibitors Against Both HIV and HSV-2 Overlapped Infections. <i>Medicinal Research Reviews</i> , 2017, 37, 149-179.	10.5	44

#	ARTICLE	IF	CITATIONS
19	Synthesis of new anionic carbosilane dendrimers via thiol-ene chemistry and their antiviral behaviour. <i>Organic and Biomolecular Chemistry</i> , 2014, 12, 3222.	2.8	41
20	Polyanionic carbosilane dendrimers prevent hepatitis C virus infection in cell culture. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 49-58.	3.3	38
21	<i>ABC1</i> gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients. <i>Pharmacogenomics</i> , 2010, 11, 1715-1723.	1.3	36
22	GCN2 Has Inhibitory Effect on Human Immunodeficiency Virus-1 Protein Synthesis and Is Cleaved upon Viral Infection. <i>PLoS ONE</i> , 2012, 7, e47272.	2.5	36
23	Regulation of Human Immunodeficiency Virus Type 1 Replication in Human T Lymphocytes by Nitric Oxide. <i>Journal of Virology</i> , 2001, 75, 4655-4663.	3.4	34
24	Pediatric HIV BioBank: A New Role of the Spanish HIV BioBank in Pediatric HIV Research. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 241-244.	1.1	33
25	Plasma IL-6 and IL-9 predict the failure of interferon- α plus ribavirin therapy in HIV/HCV-coinfected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1238-1245.	3.0	30
26	Effect of phosphodiesterase 4 inhibitors on NFAT-dependent cyclooxygenase-2 expression in human T lymphocytes. <i>Cellular Signalling</i> , 2004, 16, 1363-1373.	3.6	27
27	Antiviral Properties Against HIV of Water Soluble Copper Carbosilane Dendrimers and their EPR Characterization. <i>Current Medicinal Chemistry</i> , 2012, 19, 4984-4994.	2.4	27
28	HIV-1 antiviral behavior of anionic PPI metallo-dendrimers with EDA core. <i>European Journal of Medicinal Chemistry</i> , 2015, 98, 139-148.	5.5	26
29	Gold nanoparticles stabilized by cationic carbosilane dendrons: synthesis and biological properties. <i>Dalton Transactions</i> , 2017, 46, 8736-8745.	3.3	25
30	A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART. <i>PLoS ONE</i> , 2015, 10, e0141456.	2.5	24
31	In silico search, chemical characterization and immunogenic evaluation of amino-terminated G4-PAMAM-HIV peptide complexes using three-dimensional models of the HIV-1 gp120 protein. <i>Colloids and Surfaces B: Biointerfaces</i> , 2019, 177, 77-93.	5.0	23
32	Dendronized magnetic nanoparticles for HIV-1 capture and rapid diagnostic. <i>Colloids and Surfaces B: Biointerfaces</i> , 2019, 181, 360-368.	5.0	22
33	Mitochondrial Haplogroups Are Associated With Clinical Pattern of AIDS Progression in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 178-183.	2.1	21
34	Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization. <i>PLoS ONE</i> , 2017, 12, e0186602.	2.5	20
35	Anti-Human Immunodeficiency Virus Activity of Thiol-Ene Carbosilane Dendrimers and Their Potential Development as a Topical Microbicide. <i>Journal of Biomedical Nanotechnology</i> , 2015, 11, 1783-1798.	1.1	19
36	Carbosilane dendrons with fatty acids at the core as a new potential microbicide against HSV-2/HIV-1 co-infection. <i>Nanoscale</i> , 2017, 9, 17263-17273.	5.6	19

#	ARTICLE	IF	CITATIONS
37	Polyanionic N-donor ligands as chelating agents in transition metal complexes: synthesis, structural characterization and antiviral properties against HIV. <i>Dalton Transactions</i> , 2012, 41, 6488.	3.3	18
38	Plasma Drug Concentrations and Virologic Evaluations after Stopping Treatment with Nonnucleoside Reverse Transcriptase Inhibitors in HIV Type 1-Infected Children. <i>Clinical Infectious Diseases</i> , 2008, 46, 1601-1608.	5.8	16
39	Dysregulation of the Immune System in HIV/HCV-Coinfected Patients According to Liver Stiffness Status. <i>Cells</i> , 2018, 7, 196.	4.1	14
40	Lower expression of plasma-derived exosome miR-21 levels in HIV-1 elite controllers with decreasing CD4 T cell count. <i>Journal of Microbiology, Immunology and Infection</i> , 2019, 52, 667-671.	3.1	14
41	Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 1081-1086.	3.0	13
42	Specific Legislation on Biobanks in Spain. <i>Biopreservation and Biobanking</i> , 2015, 13, 207-211.	1.0	13
43	Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B. <i>PLoS ONE</i> , 2017, 12, e0184929.	2.5	13
44	Lack of Association of HIV-1 Biological or Molecular Properties With Neurotropism for Brain Cells. <i>Journal of Molecular Neuroscience</i> , 2006, 29, 131-144.	2.3	11
45	Promising PEGylated cationic dendrimers for delivery of miRNAs as a possible therapy against HIV-1 infection. <i>Journal of Nanobiotechnology</i> , 2021, 19, 158.	9.1	10
46	CCR5+ CD8 T-cell levels and monocyte activation precede the onset of acute coronary syndrome in HIV-infected patients on antiretroviral therapy. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1141-1149.	3.4	9
47	VDR rs2228570 Polymorphism Is Related to Non-Progression to AIDS in Antiretroviral Therapy Na ⁺ ve HIV-Infected Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 311.	2.4	9
48	Combination of G2-S16 dendrimer/dapivirine antiretroviral as a new HIV-1 microbicide. <i>Future Medicinal Chemistry</i> , 2019, 11, 3005-3013.	2.3	9
49	Mild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: A prospective study. <i>Journal of Infection</i> , 2020, 80, 99-110.	3.3	9
50	ACSM4 Polymorphisms Are Associated With Rapid AIDS Progression in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 27-32.	2.1	8
51	Increased CD127+ and decreased CD57+ T cell expression levels in HIV-infected patients on NRTI-sparing regimens. <i>Journal of Translational Medicine</i> , 2017, 15, 259.	4.4	6
52	Reasons for Not Participating in a Phase 1 Preventive HIV Vaccine Study in a Resource-Rich Country. <i>AIDS Patient Care and STDs</i> , 2012, 26, 379-382.	2.5	4
53	Antiviral Action of Sulfonate Anionic Carbosilane Dendrimer as a Topical Microbicide against HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A205-A205.	1.1	4
54	Dendronized PLGA nanoparticles with anionic carbosilane dendrons as antiviral agents against HIV infection. <i>RSC Advances</i> , 2016, 6, 73817-73826.	3.6	4

#	ARTICLE	IF	CITATIONS
55	Vector replication and expression of HIV-1 antigens by the HIV/AIDS vaccine candidate MVA-B is not affected by HIV-1 protease inhibitors. <i>Virus Research</i> , 2012, 167, 391-396.	2.2	3
56	The Spanish HIV HGM BioBank (SHIVBB). <i>Biopreservation and Biobanking</i> , 2013, 11, 253-254.	1.0	3
57	<i>IL7RA</i> polymorphisms are not associated with AIDS progression. <i>European Journal of Clinical Investigation</i> , 2017, 47, 719-727.	3.4	3
58	Role of toll-like receptor 4 Asp299Gly polymorphism in the development of cardiovascular diseases in HIV-infected patients. <i>Aids</i> , 2018, 32, 1035-1041.	2.2	3
59	High Plasma Levels of sTNF-R1 and CCL11 Are Related to CD4+ T-Cells Fall in Human Immunodeficiency Virus Elite Controllers With a Sustained Virologic Control. <i>Frontiers in Immunology</i> , 2018, 9, 1399.	4.8	3
60	Inside Cover: Gene Therapy in HIV-Infected Cells to Decrease Viral Impact by Using an Alternative Delivery Method (ChemMedChem 6/2010). <i>ChemMedChem</i> , 2010, 5, 798-798.	3.2	2
61	Bryostatin Activates HIV-1 Latent Expression in Human Astrocytes through a PKC and NF- κ B-Dependent Mechanism. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A285-A285.	1.1	2
62	DBP rs16846876 and rs12512631 polymorphisms are associated with progression to AIDS na \ddot{A} ve HIV-infected patients: a retrospective study. <i>Journal of Biomedical Science</i> , 2019, 26, 83.	7.0	2
63	Where does free infective HIV-1 rebound come from?. <i>Aids</i> , 2001, 15, 657.	2.2	2
64	Brief Report: CYP27B1 rs10877012 T Allele Was Linked to Non-AIDS Progression in ART-Na \ddot{A} ve HIV-Infected Patients: A Retrospective Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 659-664.	2.1	2
65	Broad-spectrum Anti-HIV-1 Activity of Anionic Carbosilane Dendrimers and Synergy in Combination with Maraviroc and Tenofovir as Topical Microbicide. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A144-A144.	1.1	1
66	Safety of G2-S16 Polyanionic Carbosilane Dendrimer as Possible HIV-1 Vaginal Microbicide. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2565.	4.1	1
67	Prevention of Herpesviridae Infections by Cationic PEGylated Carbosilane Dendrimers. <i>Pharmaceutics</i> , 2022, 14, 536.	4.5	1
68	High Plasma sTNF-R1 Level Is Related to Loss of Natural HIV Control in Long-Term Elite Controllers. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 858872.	3.9	1
69	HIV HGM biobank as a research platform for paediatric infectious diseases and COVID-19 pandemic. <i>AIDS Research and Therapy</i> , 2022, 19, .	1.7	1